Records containing: Multiple Myeloma

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

All FDA submission records EMA medicine records ClinicalTrials.gov record updates ClinicalTrials.gov records with results posted

CLINICAL_TRIALS study record update · 2020-05-19
Multiple Myeloma Patients and Their HCPs Tested eHealth Support
CLINICAL_TRIALS study record update · 2020-05-18
Vorinostat (SAHA) and Lenalidomide After Autologous Transplant for Patients With Multiple Myeloma
CLINICAL_TRIALS study record update · 2020-05-18
Non-steroidal Anti-inflammatory Drugs (Meloxicam) to Mobilize Hematopoietic Stem Cells: A Phase II Randomized Trial
CLINICAL_TRIALS study record update · 2020-05-14
Quality of Life and Psychological Distress in Patients With Multiple Myeloma and Their Caregivers
CLINICAL_TRIALS study record update · 2020-05-12
A Phase 1, Open-label, Multicenter, Randomized, 2-Period, Crossover Study to Evaluate the Bioequivalence and Food Effect Bioavailability of CC-486 (Oral Azacitidine) Tablets in Adult Cancer Subjects
Organize your saved records without ads with Plus.
CLINICAL_TRIALS study record update · 2020-05-12
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
CLINICAL_TRIALS study record update · 2020-05-11
Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN #07LT)
CLINICAL_TRIALS study record update · 2020-05-06
Pilot Study of an Oral Chemotherapy Teaching Tool to Improve Adherence in Patients With Multiple Myeloma
CLINICAL_TRIALS study record update · 2020-05-04
Long-Term Follow-up Protocol for Subjects Treated With a CAR T-Cell Product on a Juno-Sponsored Clinical Trial
CLINICAL_TRIALS study record update · 2020-04-29
Phase II, Multicenter, Open Label, Clinical Trial of the Anti-PD1 Monoclonal Antibody Pembrolizumab (MK-3475) as Consolidation Therapy in Multiple Myeloma Patients With Residual Disease After Treatment
CLINICAL_TRIALS study record update · 2020-04-28
A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants With Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)
CLINICAL_TRIALS study record update · 2020-04-21
A Phase IIb, Multicenter, Open-Label, Safety and Efficacy Study of High Dose Melphalan HCL for Injection (Propylene Glycol-Free)for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation
CLINICAL_TRIALS study record update · 2020-04-10
Detection and Pathogenesis of Novel Protein F
CLINICAL_TRIALS study record update · 2020-04-08
An Open-label, Multi-center, Expanded Treatment Protocol of Oral Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed, and Relapsed and Refractory Multiple Myeloma
CLINICAL_TRIALS study record update · 2020-04-07
A Phase 1, Multicenter, Open Label, Dose-escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LDDEX) in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
CLINICAL_TRIALS study record update · 2020-04-06
Assessment of the Antitumour Effect of Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse: Prospective Clinical Trial of the GEM/PETHEMA Group
CLINICAL_TRIALS study record update · 2020-03-30
A Phase 1 Study of ACTR087, an Autologous T Cell Product, in Combination With SEA-BCMA, a Monoclonal Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma
CLINICAL_TRIALS study record update · 2020-03-27
Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial
CLINICAL_TRIALS study record update · 2020-03-16
Phase I Study of Dasatinib in Recipients of Autologous Stem Cell Transplantation for Hematologic Malignancies.
CLINICAL_TRIALS study record update · 2020-03-12
A Randomized Phase I/II Study of BI-505 in Conjunction With High-dose Melphalan and Autologous Stem Cell Transplantation for Multiple Myeloma
CLINICAL_TRIALS study record update · 2020-03-10
Assessing the Feasibility and Benefits of a Physical Activity Intervention for Advanced Multiple Myeloma Patients
CLINICAL_TRIALS study record update · 2020-03-04
Combined HLA-matched Bone Marrow and Kidney Transplantation for Multiple Myeloma With Renal Failure
CLINICAL_TRIALS study record update · 2020-03-04
A Phase # Study Evaluating Safety and Efficacy of C-CAR088 Treatment in Subjects With Relapsed or Refractory Multiple Myeloma
CLINICAL_TRIALS study record update · 2020-03-04
An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)
CLINICAL_TRIALS study record update · 2020-03-04
Phase 2 Study Of Autologous T Cells Engineered To Express an Anti-CD19 Chimeric Antigen Receptor (CART-19) Following First-line Autologous Stem Cell Transplantation for High-risk Multiple Myeloma